Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program-Reference-Cited by-同舟云学术

Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program

Published:2023-07-18 Issue:7 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Satlin Michael J.¹^ORCID,Simner Patricia J.²^ORCID,Slover Christine M.³,Yamano Yoshinori⁴,Nagata Tsutae D.⁴,Portsmouth Simon³^ORCID

Affiliation:

1. Transplant-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA

2. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

3. Shionogi Inc., Florham Park, New Jersey, USA

4. Shionogi & Co., Ltd., Osaka, Japan

Abstract

Cefiderocol is an option for infections caused by multidrug-resistant Pseudomonas aeruginosa , but its in vitro activity against these isolates and its clinical effectiveness for isolates with MICs of >1 μg/mL is unclear. We investigated the in vitro activity of cefiderocol against P. aeruginosa isolates collected from patients treated with cefiderocol through the compassionate use program and assessed physician-reported clinical response and 28-day all-cause mortality by cefiderocol MIC values. P. aeruginosa isolates underwent susceptibility testing to cefiderocol and comparator agents by using reference broth microdilution.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00194-23

Reference41 articles.

1. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

2. How to manage Pseudomonas aeruginosa infections

3. The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update

4. World Health Organization Regional Office for Europe European Centre for Disease Prevention and Control. 2022. Antimicrobial resistance surveillance Europe. https://www.ecdc.europa.eu/sites/default/files/documents/Joint-WHO-ECDC-AMR-report-2022.pdf. Retrieved 3 October 2022.

5. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cefiderocol for resistant Gram negatives: linking in vitro activity with clinical effectiveness;Clinical Microbiology and Infection;2024-02

2. Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections;Microbiology Spectrum;2024-01-11

3. The Use of Cefiderocol as Salvage Therapy in an Infant Receiving ECMO and Continuous Renal Replacement Therapy;Antibiotics;2023-12-30

4. Management strategies for severe Pseudomonas aeruginosa infections;Current Opinion in Infectious Diseases;2023-10-12

5. Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience;Journal of Antimicrobial Chemotherapy;2023-10-09